Robert J. Temple

3.5k total citations · 2 hit papers
27 papers, 1.2k citations indexed

About

Robert J. Temple is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Robert J. Temple has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Economics and Econometrics, 6 papers in Pediatrics, Perinatology and Child Health and 6 papers in Pharmacology. Recurrent topics in Robert J. Temple's work include Statistical Methods in Clinical Trials (6 papers), Pharmaceutical studies and practices (6 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Robert J. Temple is often cited by papers focused on Statistical Methods in Clinical Trials (6 papers), Pharmaceutical studies and practices (6 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Robert J. Temple collaborates with scholars based in United States, Switzerland and United Kingdom. Robert J. Temple's co-authors include Jessica P. J. Larwood, Nicholas Jones, Lydia Bourouiba, Zeshan Qureshi, Trisha Greenhalgh, Janet Woodcock, Ellis F. Unger, Pamela E. Scott, Tzu‐Yun McDowell and Ruth J. Geller and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Biological Chemistry.

In The Last Decade

Robert J. Temple

27 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Two metres or one: what is the evidence for physical distancing in covid-19?

2020 267 citations Nicholas Jones, Zeshan Qureshi et al. BMJ profile →
Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs

2018 233 citations Pamela E. Scott, Ellis F. Unger et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert J. Temple United States	15	290	220	173	164	152	27	1.2k
Preciosa M. Coloma Netherlands	25	247 0.9×	131 0.6×	213 1.2×	125 0.8×	124 0.8×	46	1.9k
Vittorio Bertelè Italy	28	620 2.1×	222 1.0×	119 0.7×	205 1.3×	155 1.0×	85	2.2k
Rosa Gini Italy	26	401 1.4×	382 1.7×	263 1.5×	122 0.7×	89 0.6×	123	2.3k
Peter Arlett Netherlands	21	607 2.1×	181 0.8×	237 1.4×	103 0.6×	249 1.6×	54	1.8k
Ghada Miremont‐Salamé France	22	182 0.6×	138 0.6×	125 0.7×	107 0.7×	142 0.9×	76	1.8k
Hsiao‐Hui Tsou Taiwan	24	240 0.8×	134 0.6×	262 1.5×	135 0.8×	113 0.7×	80	1.8k
Manfred Hauben United States	26	270 0.9×	117 0.5×	297 1.7×	102 0.6×	181 1.2×	77	2.4k
Judith A. Racoosin United States	15	231 0.8×	217 1.0×	232 1.3×	61 0.4×	107 0.7×	27	2.1k
Alun Bedding United Kingdom	16	184 0.6×	91 0.4×	316 1.8×	167 1.0×	52 0.3×	32	1.3k
Susan T. Sacks United States	16	97 0.3×	140 0.6×	130 0.8×	136 0.8×	91 0.6×	39	1.8k

Countries citing papers authored by Robert J. Temple

Since Specialization

Citations

This map shows the geographic impact of Robert J. Temple's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Temple with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Temple more than expected).

Fields of papers citing papers by Robert J. Temple

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Temple. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Temple. The network helps show where Robert J. Temple may publish in the future.

Co-authorship network of co-authors of Robert J. Temple

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Temple. A scholar is included among the top collaborators of Robert J. Temple based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Temple. Robert J. Temple is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Temple, Robert J., et al.. (2022). Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021. JAMA Network Open. 5(11). e2239336–e2239336. 13 indexed citations

Jones, Nicholas, Zeshan Qureshi, Robert J. Temple, et al.. (2020). Two metres or one: what is the evidence for physical distancing in covid-19?. BMJ. 370. m3223–m3223. 267 indexed citations breakdown →

Scott, Pamela E., Ellis F. Unger, Marjorie Jenkins, et al.. (2018). Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs. Journal of the American College of Cardiology. 71(18). 1960–1969. 233 indexed citations breakdown →

Mathis, Mitchell, et al.. (2017). The US Food and Drug Administration’s Perspective on the New Antipsychotic Pimavanserin. The Journal of Clinical Psychiatry. 78(6). e668–e673. 29 indexed citations

Khin, Ni A., Phillip D. Kronstein, Peiling Yang, et al.. (2015). Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials. The Journal of Clinical Psychiatry. 76(8). 1060–1063. 14 indexed citations

Kronstein, Phillip D., Ni A. Khin, Eric H. Chang, et al.. (2015). Summary of Findings From the FDA Regulatory Science Forum on Measuring Sexual Dysfunction in Depression Trials. The Journal of Clinical Psychiatry. 76(8). 1050–1059. 10 indexed citations

Zhang, Jing, Mitchell Mathis, André J. Jackson, et al.. (2014). The US Food and Drug Administration’s Perspective on the New Antidepressant Vortioxetine. The Journal of Clinical Psychiatry. 76(1). 8–14. 26 indexed citations

Hess, Connie N., Matthew T. Roe, C. Michael Gibson, et al.. (2014). Independent data monitoring committees: Preparing a path for the future. American Heart Journal. 168(2). 135–141.e1. 13 indexed citations

Woodcock, Janet, et al.. (2011). New FDA Regulation to Improve Safety Reporting in Clinical Trials. New England Journal of Medicine. 365(1). 3–5. 38 indexed citations

10.

Temple, Robert J.. (1997). When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?. Controlled Clinical Trials. 18(6). 613–620. 36 indexed citations

11.

Peck, Carl C., William H. Barr, Leslie Z. Benet, et al.. (1994). Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. The Journal of Clinical Pharmacology. 34(2). 111–119. 37 indexed citations

12.

Kelloff, Gary J., John R. Johnson, James A. Crowell, et al.. (1994). Guidance for development of chemopreventive agents. Journal of Cellular Biochemistry. 56(S20). 25–31. 7 indexed citations

13.

Kessler, David A., et al.. (1994). Therapeutic-Class Wars -- Drug Promotion in a Competitive Marketplace. New England Journal of Medicine. 331(20). 1350–1353. 92 indexed citations

14.

Peck, Carl C., William H. Barr, Leslie Z. Benet, et al.. (1992). Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Journal of Pharmaceutical Sciences. 81(6). 605–610. 49 indexed citations

15.

Peck, Carl C., William H. Barr, Leslie Z. Benet, et al.. (1992). Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clinical Pharmacology & Therapeutics. 51(4). 465–473. 141 indexed citations

16.

Peck, Carl C., William H. Barr, Leslie Z. Benet, et al.. (1992). Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Pharmaceutical Research. 9(6). 826–833. 41 indexed citations

17.

Temple, Robert J.. (1991). Access, Science, and Regulation. Drug Information Journal. 25(1). 1–11. 2 indexed citations

18.

Peck, Carl C., et al.. (1989). Understanding comparisons of drug introductions between the united states and the united kingdom. Clinical Pharmacology & Therapeutics. 46(2). 139–145. 6 indexed citations

19.

Temple, Robert J.. (1981). THE EFFECT OF THE DRUG REGULATION REFORM ACT OF 1978 ON CLINICAL RESEARCH, DRUG AVAILABILITY, AND THE PUBLIC HEALTH. Annals of the New York Academy of Sciences. 368(1). 175–186. 3 indexed citations

20.

Temple, Robert J., H. E. Umbarger, & Boris Magasanik. (1965). The Effect of l-Valine on Enzyme Synthesis in Escherichia coli K-12. Journal of Biological Chemistry. 240(3). 1219–1224. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact